Newborn babies who need intensive medical care are often sheltered into a special area of the hospital called Neonatal Intensive Care Unit (NICU). In this structure, babies are regularly subject to conditions that would be considered harmful by older children and adults. In the last years, many clinical researches have paid particular attention to effectiveness of various pharmacological therapies, regularly used in neonatal intensive care that have sharply reduced mortality of newborn and preterm infants. Although there are many classes of drugs used for the treatment of different diseases (sepsis, pain, seizures, pulmonary hypertension and infection), the fledgling population is more difficult to handle because there are many physiological changes that happen in infants which do not occur at any other time of life. Furthermore, there are many drugs used during the first stage of life, able to induce various toxic effects on the principal organs and apparatus. For example, there are many relationships between amikacina serum levels and central conduction time in brainstem auditory evoked potentials within therapeutic range levels in newborns as index of drug toxicity in brainstem auditory centers in neonatally exposed infants. In this chapter, we will focus mainly on the principal pharmacological strategies used for dealing with neonatal diseases in the Neonatal Intensive Care Unit.

Plescia, F., Lavanco, G., Brancato, A., Cannizzaro, C., Dispenza, F., Mucia, M., et al. (2017). Pharmacological therapy of newborn babies admitted to the neonatal intensive care unit. In Neonatal Intensive Care Units (NICUs): Clinical and Patient Perspectives, Levels of Care and Emerging Challenges (pp. 91-122). Nova Science Publishers, Inc..

Pharmacological therapy of newborn babies admitted to the neonatal intensive care unit

Plescia, Fulvio
Writing – Original Draft Preparation
;
Lavanco, Gianluca
Membro del Collaboration Group
;
Brancato, Anna
Membro del Collaboration Group
;
Cannizzaro, Carla
Methodology
;
Dispenza, Francesco
Membro del Collaboration Group
;
Mucia, Marianna
Membro del Collaboration Group
;
Salvago, Pietro
Membro del Collaboration Group
;
Sireci, Federico
Membro del Collaboration Group
;
Rizzo, Serena
Membro del Collaboration Group
;
Cavallaro, Angela
Writing – Review & Editing
2017-01-01

Abstract

Newborn babies who need intensive medical care are often sheltered into a special area of the hospital called Neonatal Intensive Care Unit (NICU). In this structure, babies are regularly subject to conditions that would be considered harmful by older children and adults. In the last years, many clinical researches have paid particular attention to effectiveness of various pharmacological therapies, regularly used in neonatal intensive care that have sharply reduced mortality of newborn and preterm infants. Although there are many classes of drugs used for the treatment of different diseases (sepsis, pain, seizures, pulmonary hypertension and infection), the fledgling population is more difficult to handle because there are many physiological changes that happen in infants which do not occur at any other time of life. Furthermore, there are many drugs used during the first stage of life, able to induce various toxic effects on the principal organs and apparatus. For example, there are many relationships between amikacina serum levels and central conduction time in brainstem auditory evoked potentials within therapeutic range levels in newborns as index of drug toxicity in brainstem auditory centers in neonatally exposed infants. In this chapter, we will focus mainly on the principal pharmacological strategies used for dealing with neonatal diseases in the Neonatal Intensive Care Unit.
2017
Plescia, F., Lavanco, G., Brancato, A., Cannizzaro, C., Dispenza, F., Mucia, M., et al. (2017). Pharmacological therapy of newborn babies admitted to the neonatal intensive care unit. In Neonatal Intensive Care Units (NICUs): Clinical and Patient Perspectives, Levels of Care and Emerging Challenges (pp. 91-122). Nova Science Publishers, Inc..
File in questo prodotto:
File Dimensione Formato  
978-1-53612-057-8_eBook.pdf

Solo gestori archvio

Dimensione 3.31 MB
Formato Adobe PDF
3.31 MB Adobe PDF   Visualizza/Apri   Richiedi una copia

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/10447/276443
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus 2
  • ???jsp.display-item.citation.isi??? ND
social impact